Characteristics of antipsychotic medication prescribing on inpatient obstetric floors

Cohen LS, Viguera AC, McInerney KA, Kwiatkowski MA, Murphy SK, Lemon EL, Hernandez-Diaz S (2015) Establishment of the National Pregnancy Registry for Atypical Antipsychotics. J Clin Psychiatry 76(7):986–989 Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH (2015) Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol 125(5):1224–1235 Einarson A, Selby P, Koren G (2001) Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 26(1):44–48 Kulkarni J, Storch A, Baraniuk A, Gilbert H, Gavrilidis E, Worsley R (2015) Antipsychotic use in pregnancy. Expert Opin Pharmacother 16(9):1335–1345 Sutter-Dallay AL, Bales M, Pambrun E, Glangeaud-Freudenthal NM, Wisner KL, Verdoux H (2015) Impact of prenatal exposure to psychotropic drugs on neonatal outcome in infants of mothers with serious psychiatric illnesses. J Clin Psychiatry 76(7):967–973 Toh S, Li Q, Cheetham TC, Cooper WO, Davis RL, Dublin S, Hammad TA, Li DK, Pawloski PA, Pinheiro SP, Raebel MA, Scott PE, Smith DH, Bobo WV, Lawrence JM, Dashevsky I, Haffenreffer K, Avalos LA, Andrade SE (2013) Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001–2007: a population-based study of 585,615 deliveries. Arch Womens Ment Health 16(2):149–157